Thymic-derived tolerizing dendritic cells are upregulated in the spleen upon treatment with intravenous immunoglobulin in a murine model of immune thrombocytopenia |
| |
| Authors: | Rick Kapur Rukhsana Aslam Michael Kim Li Guo Heyu Ni George B. Segel |
| |
| Affiliation: | 1. The Toronto Platelet Immunobiology Group, Keenan Research Centre for Biomedical Science of St. Michael’s Hospital, Toronto, ON, Canada;2. Canadian Blood Services, Toronto, ON, Canada;3. Department of Medicine, University of Toronto, Toronto, ON, Canada;4. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada;5. Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA |
| |
| Abstract: | ![]()
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by low platelet counts. First-line treatment includes intravenous immunoglobulin (IVIg), however, its working mechanism remains incompletely understood. We investigated splenic and thymic dendritic cell (DC) subsets upon IVIg treatment in a well-characterized active murine model of ITP. During active disease, there was a significant peripheral deficiency of splenic tolerizing SIRPα+ DCs which could be rescued by IVIg therapy, increasing platelet counts. These splenic tolerizing DC changes were associated with an abrogation of the thymic-retention of tolerizing DCs, suggesting that IVIg may raise platelet counts in ITP by modulating peripheral numbers of tolerizing DCs. |
| |
| Keywords: | IVIg Dendritic cells immune thrombocytopenia |
|
|
